Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients
Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares are higher during Tuesday’s premarket session as the company is discussing positive results from its recent clinical study.
Positive Data From Inflammatory Bowel Disease Study
Teva and Sanofi SA (NASDAQ:SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.
The study demonstrated durable clinical efficacy maintained over 44 weeks in patients with ulcerative colitis and Crohn’s disease.
The study involved 130 patients who initially responded to duvakitug in the induction phase, and both doses of duvakitug were well tolerated.
Patients were re-randomized to receive either a 450 mg or 900 mg subcutaneous dose of duvakitug every four weeks for up to a total of 58 weeks of exposure.
Ulcerative colitis: 58% (900 mg) and 47% (450 mg) of patients treated with duvakitug achieved the primary endpoint of clinical remission.
Crohn’s disease: 55% (900 mg) and 41% (450 mg) of patients treated with duvakitug achieved the primary endpoint of endoscopic response.
In both patient groups, consistent benefits were observed across additional efficacy endpoints.
Technical Analysis
Currently, the stock is trading 6.3% below its 20-day simple moving average (SMA) and 10.5% below its 100-day SMA, indicating short-term weakness. Shares have increased 105.07% over the past 12 months and are currently positioned closer to their 52-week highs than lows.
The RSI is at 50.00, which is considered neutral territory, while MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $37.50
- Key Support: $30.50
Analyst Consensus & Recent Actions
The stock carries a Buy Rating with an average price target of $31.75. Recent analyst moves include:
- Goldman Sachs: Buy (Raises Target to $45)
- Barclays: Overweight (Raises Target to $38)
- Scotiabank: Sector Outperform (Raises Target to $40)
Top ETF Exposure
- iShares MSCI Israel ETF (NYSE:EIS): 9.59% Weight
- ARK Israel Innovative Technology ETF (BATS:IZRL): 2.37% Weight
- VanEck Israel ETF (NYSE:ISRA): 10.48% Weight
TEVA Price Action: Teva Pharmaceutical shares are up 2.85% at $34.94 and SNY 0.26% at $46.13 during premarket trading on Tuesday, according to Benzinga Pro data.
Photo via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's sudden resignation shrouded in suspicion: Did the White House secretly intervene? Is a return possible in the future?
Only a few days separated Jensen Huang’s strong support from the board last Sunday and his late-night resignation on Wednesday. Multiple reports of the Wednesday night Nvidia board meeting were co-authored by Washington-based journalists—who do not typically cover Nvidia—fueling rumors of "White House pressure and information leaks." Huang’s unique value lies in leveraging his personal reputation to secure the supply chain and drive the implementation of technological roadmaps, making him difficult to replace. Some analysts note that, drawing on examples such as Steve Jobs’ return to Apple, it is possible that Huang may come back in the future.
Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
Crypto prices
More
